 Stephanie Nakano
Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 9 | 2025 | 755 | 1.690 |
Why?
| | Cardiomyopathy, Dilated | 5 | 2019 | 389 | 1.440 |
Why?
| | Heart Ventricles | 6 | 2020 | 790 | 1.160 |
Why?
| | Heart Failure | 9 | 2025 | 2237 | 1.140 |
Why?
| | Phosphodiesterase 3 Inhibitors | 3 | 2019 | 14 | 1.100 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 46 | 1.070 |
Why?
| | Myocardium | 3 | 2017 | 1002 | 1.070 |
Why?
| | Cardiomyopathy, Hypertrophic | 6 | 2023 | 143 | 0.980 |
Why?
| | Milrinone | 2 | 2021 | 29 | 0.670 |
Why?
| | Troponin I | 1 | 2019 | 81 | 0.600 |
Why?
| | Myocytes, Cardiac | 3 | 2019 | 526 | 0.600 |
Why?
| | Graft Rejection | 1 | 2022 | 624 | 0.590 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 851 | 0.500 |
Why?
| | Adenylyl Cyclases | 1 | 2016 | 87 | 0.500 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2016 | 89 | 0.500 |
Why?
| | Heart-Lung Transplantation | 2 | 2025 | 14 | 0.480 |
Why?
| | Myocardial Contraction | 4 | 2025 | 341 | 0.480 |
Why?
| | Down-Regulation | 2 | 2017 | 657 | 0.480 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 545 | 0.470 |
Why?
| | Calcium | 1 | 2019 | 1200 | 0.410 |
Why?
| | Lung Transplantation | 2 | 2025 | 313 | 0.380 |
Why?
| | Genetic Therapy | 1 | 2014 | 297 | 0.380 |
Why?
| | Death, Sudden, Cardiac | 4 | 2023 | 185 | 0.380 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 698 | 0.360 |
Why?
| | Disease Management | 2 | 2025 | 629 | 0.350 |
Why?
| | Societies, Medical | 2 | 2025 | 820 | 0.350 |
Why?
| | Child | 17 | 2025 | 21989 | 0.350 |
Why?
| | Child, Preschool | 10 | 2023 | 11105 | 0.350 |
Why?
| | RNA | 1 | 2016 | 921 | 0.320 |
Why?
| | Defibrillators, Implantable | 2 | 2023 | 315 | 0.280 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2607 | 0.260 |
Why?
| | Biomarkers | 1 | 2018 | 4154 | 0.260 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2017 | 346 | 0.250 |
Why?
| | Sphingosine | 1 | 2025 | 46 | 0.230 |
Why?
| | Lysophospholipids | 1 | 2025 | 80 | 0.220 |
Why?
| | Mitochondria, Heart | 1 | 2025 | 102 | 0.220 |
Why?
| | Cystic Fibrosis | 1 | 2014 | 1114 | 0.220 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2025 | 135 | 0.210 |
Why?
| | Perfusion | 1 | 2025 | 214 | 0.210 |
Why?
| | Humans | 25 | 2025 | 137782 | 0.210 |
Why?
| | Electrocardiography | 2 | 2023 | 629 | 0.190 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2023 | 133 | 0.190 |
Why?
| | Pseudohypoparathyroidism | 1 | 2022 | 3 | 0.190 |
Why?
| | Male | 14 | 2025 | 67906 | 0.170 |
Why?
| | Infant | 4 | 2023 | 9482 | 0.170 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 333 | 0.170 |
Why?
| | Blalock-Taussig Procedure | 1 | 2020 | 5 | 0.170 |
Why?
| | Heart Bypass, Right | 1 | 2020 | 17 | 0.160 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 66 | 0.160 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 41 | 0.160 |
Why?
| | Ventricular Septum | 1 | 2019 | 8 | 0.160 |
Why?
| | Exercise Test | 1 | 2022 | 632 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 326 | 0.160 |
Why?
| | General Practice | 1 | 2019 | 29 | 0.150 |
Why?
| | Resource Allocation | 1 | 2019 | 52 | 0.150 |
Why?
| | Biopsy | 1 | 2022 | 1130 | 0.150 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.150 |
Why?
| | Cardiomyopathies | 1 | 2022 | 350 | 0.140 |
Why?
| | Educational Status | 1 | 2020 | 470 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1586 | 0.140 |
Why?
| | Calcium-Binding Proteins | 2 | 2016 | 218 | 0.140 |
Why?
| | Female | 12 | 2023 | 73465 | 0.130 |
Why?
| | Adolescent | 8 | 2023 | 21574 | 0.130 |
Why?
| | Phosphorylation | 2 | 2019 | 1759 | 0.130 |
Why?
| | Risk | 1 | 2019 | 912 | 0.130 |
Why?
| | Genetic Markers | 1 | 2017 | 344 | 0.130 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 121 | 0.130 |
Why?
| | Ventricular Remodeling | 1 | 2018 | 268 | 0.120 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 285 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 669 | 0.120 |
Why?
| | Risk Factors | 5 | 2023 | 10407 | 0.120 |
Why?
| | Carrier Proteins | 1 | 2019 | 771 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2019 | 4193 | 0.110 |
Why?
| | Fibrosis | 1 | 2017 | 552 | 0.110 |
Why?
| | Public Health | 1 | 2019 | 588 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2019 | 554 | 0.100 |
Why?
| | Age Factors | 2 | 2020 | 3305 | 0.100 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 45 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 853 | 0.090 |
Why?
| | Blotting, Western | 1 | 2014 | 1227 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1103 | 0.090 |
Why?
| | Cohort Studies | 4 | 2023 | 5750 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2023 | 6084 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2023 | 15682 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 766 | 0.080 |
Why?
| | Young Adult | 4 | 2023 | 13240 | 0.080 |
Why?
| | Genomics | 1 | 2014 | 795 | 0.070 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 553 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2020 | 2659 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2019 | 10837 | 0.070 |
Why?
| | Risk Assessment | 3 | 2023 | 3461 | 0.070 |
Why?
| | Echocardiography | 2 | 2019 | 644 | 0.060 |
Why?
| | Prognosis | 1 | 2014 | 4039 | 0.060 |
Why?
| | Obesity | 1 | 2019 | 2993 | 0.060 |
Why?
| | Cyclic AMP | 2 | 2019 | 234 | 0.060 |
Why?
| | Middle Aged | 2 | 2016 | 33554 | 0.050 |
Why?
| | Chromogranins | 1 | 2022 | 15 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2022 | 11 | 0.050 |
Why?
| | United States | 1 | 2019 | 14870 | 0.050 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 66 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 124 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 82 | 0.040 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2019 | 10 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 64 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 37 | 0.040 |
Why?
| | Internationality | 1 | 2019 | 155 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3569 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 889 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 844 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 660 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1266 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2734 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 509 | 0.030 |
Why?
| | Up-Regulation | 1 | 2018 | 843 | 0.030 |
Why?
| | Aged | 1 | 2014 | 24001 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4295 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5764 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 2487 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1704 | 0.020 |
Why?
| | Connexin 43 | 1 | 2012 | 32 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3290 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 99 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 182 | 0.020 |
Why?
| | Adult | 1 | 2014 | 38023 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2836 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2390 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5136 | 0.020 |
Why?
| | Animals | 2 | 2025 | 36951 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7623 | 0.020 |
Why?
| | Mice | 1 | 2025 | 17794 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5081 | 0.010 |
Why?
|
|
Nakano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|